Renal Insufficiency Market

Market Overview:

The 7 major renal insufficiency markets reached a value of US$ 9.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 22.7 Billion by 2034, exhibiting a growth rate (CAGR) of 8.6% during 2024-2034.

The renal insufficiency market has been comprehensively analyzed in IMARC's new report titled "Renal Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Renal insufficiency refers to a progressive and chronic condition in which the kidneys are unable to adequately perform their vital functions of filtering waste products and excess fluids from the blood. As a result, the illness causes a buildup of toxic substances, electrolyte imbalances, and fluid retention in the body. The symptoms of this ailment can vary depending on the severity of the ailment but may include fatigue, fluid retention, decreased urine output, swelling in the legs and ankles, memory problems, nausea, vomiting, loss of appetite, itching, shortness of breath, difficulty concentrating, skin rashes, confusion, etc. The diagnosis of renal insufficiency typically involves a combination of medical history review, clinical feature assessment, and a physical examination. Various blood workups, such as the serum creatinine test, complete blood count, blood urea nitrogen, etc., are commonly performed to evaluate kidney function and determine the underlying cause of the disease. The healthcare professional may also conduct imaging techniques, like computed tomography scans and magnetic resonance imaging, to visualize the structure of the kidneys and rule out other possible health problems.

The increasing cases of high blood pressure and diabetes, that can disrupt the blood vessels in the kidneys and impair their capability to filter waste and fluids effectively, are primarily driving the renal insufficiency market. In addition to this, the rising prevalence of obstructions in the urinary tract, including tumors, kidney stones, an enlarged prostate, etc., which can obstruct urine flow, is creating a positive outlook for the market. Moreover, the widespread adoption of angiotensin-converting enzyme inhibitors and diuretics to reduce fluid retention and slow down the progression of the disease is further bolstering the market growth. In line with this, the inflating application of erythropoiesis-stimulating agents (ESAs), owing to their several benefits, like enhanced production of red blood cells, increased hemoglobin levels, improved energy, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of peritoneal dialysis techniques, since they allow for fewer dietary restrictions with greater flexibility and independence compared to conventional hemodialysis, is expected to drive the renal insufficiency market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the renal insufficiency market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for renal insufficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the renal insufficiency market in any manner.

Key Highlights:

• Polycystic kidney disease is a prevalent cause of renal insufficiency, usually occurring in the fifth or sixth decade of life.
• The frequency rises with age and is higher among women than men.
• The largest prevalence rates are found in low- and middle-income nations, including Southeast Asia, Sub-Saharan Africa, and Latin America.
• Approximately 40% of diabetics develop renal insufficiency, with hypertension accounting for about 25% of cases.
• It raises the risk of cardiovascular disease, the primary cause of death in people with renal insufficiency.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the renal insufficiency market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the renal insufficiency market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current renal insufficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the renal insufficiency market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the renal insufficiency market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the renal insufficiency market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of renal insufficiency across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of renal insufficiency by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of renal insufficiency by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with renal insufficiency across the seven major markets?
• What is the size of the renal insufficiency patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of renal insufficiency?
• What will be the growth rate of patients across the seven major markets?
   

Renal Insufficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for renal insufficiency drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the renal insufficiency market?
• What are the key regulatory events related to the renal insufficiency market?
• What is the structure of clinical trial landscape by status related to the renal insufficiency market?
• What is the structure of clinical trial landscape by phase related to the renal insufficiency market?
• What is the structure of clinical trial landscape by route of administration related to the renal insufficiency market?